About PolyCore Therapeutics LLC

PolyCore Therapeutics LLC is a drug development company spinout from Drexel University focused on development of products for CNS disorders. The initial product in development, PCT-3010, is a biased signaling D3 agonist, a breakthrough once-a-day oral therapy for Parkinson’s disease that improves motor symptoms without development of drug tolerance or dyskinesia. The product will be utilized as monotherapy or as an adjunct to L-dopa to prolong the efficacy time of L-dopa and reduce L-dopa induced dyskinesia. This is a six billion per year market opportunity in the US.
visit | email 

Key People

Jim Harris
Co-Founder & CEO

Sandhya Kortagere
Co-Founder & CSO

Mike Saporito